Sangamo Therapeutics Inc (SGMO) - Total Liabilities
Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) has total liabilities worth $82.40 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sangamo Therapeutics Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how Sangamo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See SGMO working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Sangamo Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sangamo Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zakłady Lentex SA
WAR:LTX
|
Poland | zł93.79 Million |
|
Territorial Bancorp Inc
NASDAQ:TBNK
|
USA | $1.92 Billion |
|
Abra Information Technologies Ltd
TA:BBYL
|
Israel | ILA23.47 Million |
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
USA | $190.34 Million |
|
GaeaSoft Corp
KQ:051160
|
Korea | ₩99.94 Billion |
|
Osmanli Menkul Degerler AS
IS:OSMEN
|
Turkey | TL1.87 Billion |
|
Austral Gold Ltd
AU:AGD
|
Australia | AU$100.73 Million |
|
Pungguk Ethanol Industrial Co. Ltd
KQ:023900
|
Korea | ₩31.39 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Sangamo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SGMO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 13.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sangamo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sangamo Therapeutics Inc (1996–2024)
The table below shows the annual total liabilities of Sangamo Therapeutics Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $78.86 Million | -4.33% |
| 2023-12-31 | $82.43 Million | -69.19% |
| 2022-12-31 | $267.55 Million | -22.80% |
| 2021-12-31 | $346.58 Million | -21.44% |
| 2020-12-31 | $441.18 Million | +115.45% |
| 2019-12-31 | $204.78 Million | -8.53% |
| 2018-12-31 | $223.88 Million | +126.50% |
| 2017-12-31 | $98.84 Million | +355.57% |
| 2016-12-31 | $21.70 Million | -12.50% |
| 2015-12-31 | $24.80 Million | -32.21% |
| 2014-12-31 | $36.58 Million | +91.23% |
| 2013-12-31 | $19.13 Million | +8.45% |
| 2012-12-31 | $17.64 Million | +144.82% |
| 2011-12-31 | $7.20 Million | +1.58% |
| 2010-12-31 | $7.09 Million | -54.70% |
| 2009-12-31 | $15.66 Million | +25.72% |
| 2008-12-31 | $12.45 Million | +5.74% |
| 2007-12-31 | $11.78 Million | +66.47% |
| 2006-12-31 | $7.08 Million | -36.66% |
| 2005-12-31 | $11.17 Million | +375.68% |
| 2004-12-31 | $2.35 Million | +49.46% |
| 2003-12-31 | $1.57 Million | -20.70% |
| 2002-12-31 | $1.98 Million | -25.75% |
| 2001-12-31 | $2.67 Million | +31.11% |
| 2000-12-31 | $2.04 Million | +56.54% |
| 1999-12-31 | $1.30 Million | +107.01% |
| 1998-12-31 | $628.00K | +28.95% |
| 1997-12-31 | $487.00K | +363.81% |
| 1996-12-31 | $105.00K | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more